Authors
Latest:
Dr. Lynch on Targeting EGFR Mutation Subtypes in Lung CancerThomas J. Lynch, MD, CEO, chairman, Massachusetts General Hospital Physicians Organization, discusses targeting EGFR mutation subtypes as a frontline treatment for lung cancer.
Latest:
Precision Medicine: A Promising Future for Treating CancerThomas J. Lynch, MD, director, Yale Cancer Center, Physician-in-Chief, Smilow Cancer Hospital at Yale-New Haven, writes about precision medicine in oncology.
Latest:
Dr. Polascik on Harmonizing Genetic Testing Guidelines in Prostate CancerThomas J. Polascik, MD, a urologic oncologist at Duke University, discusses efforts that are being made to harmonize genetic testing guidelines in prostate cancer.
Latest:
Dr. Semrad on SPIDER Program to Understand Resistance to TherapiesThomas J. Semrad, MD, assistant professor, co-director, Phase I Program, UC Davis Health System, discusses the Serial Patient-Derived Xenografts to Understand Cancer Therapy Resistance (SPIDER) program at UC Davis Health System, aimed at understanding patient resistance to cancer therapies.
Latest:
Finding the Optimal Therapeutic Sequence for Advanced Hepatocellular CarcinomaSeveral breakthroughs in recent years have rapidly shifted the treatment landscape for advanced HCC.
Latest:
Dr. Thomas LeBlanc on Patient Shared Decision-Making in Hematologic MalignanciesThomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.
Latest:
Dr. Lynch on the Goals of Bristol-Myers SquibbThomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses goals at Bristol-Myers Squibb.
Latest:
Dr. Churilla on Impact of Health Insurance Status on Patients With HNSCCThomas M. Churilla, MD, Department of Radiation Oncology, Fox Chase Cancer Center, discusses a study exploring the impact of health insurance status on the presentation, local management, and outcomes of patients with head and neck cancer.
Latest:
Dr. Marron on the Population Included in a Phase 1 Study of PGV-001 Neoantigen Cancer VaccineThomas Urban Marron, MD, PhD, describes the patient population included in a phase 1 study examining the use of PGV-001, a neoantigen cancer vaccine, across different malignancies.
Latest:
Treatment Options for Newly Diagnosed Metastatic Urothelial CarcinomaExpert perspectives on optimal treatment approaches in patients with newly diagnosed metastatic urothelial carcinoma.
Latest:
Dr Powles on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial CancerThomas Powles, MD, MBBS, MRCP, discusses the use of enfortumab vedotin plus pembrolizumab in urothelial carcinoma based on data from the KEYNOTE-A39 trial.
Latest:
Understanding Unprecedented Data in Genitourinary Cancers From ESMO 2023: Dr PowlesOncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Latest:
Performance Metrics in OncologyIn 2011, the Medicare Electronic Health Record Incentive Program began paying physicians and hospitals for the measurement and reporting of performance metrics through the utilization of certified electronic medical record software.
Latest:
Metadata: An Orwellian Big Brother within Electronic Medical RecordsConsider this hypothetical situation: A patient with new onset of a major depression is evaluated by a physician who has found no evidence of suicidal ideation.
Latest:
Dr. Uldrick on Rituximab Plus Liposomal Doxorubicin in HIV-Infected Patients With KSHV-MCDThomas S. Uldrick, MD, staff clinician, HIV and AIDS Malignancy Branch, Center for Cancer Research at the National Institutes of Health, discusses long-term data from a study examining rituximab plus liposomal doxorubicin in HIV-infected patients with Kaposi sarcoma (KS) herpes virus-associated multicentric Castleman disease.
Latest:
Thomas Dubensky on How ADU-S100 Activates STINGThomas W. Dubensky Jr, PhD, chief scientific officer, Aduro Biotech, discusses a study of ADU-S100 and how it activates the human STING receptor, which is found to have presence in multiple tumor types.
Latest:
Dr. Flaig on Immune Checkpoint Inhibitors in Advanced Bladder CancerThomas W. Flaig, MD, discusses the utility of immune checkpoint inhibitors in advanced bladder cancer.
Latest:
Dr. LeBlanc Discusses End-of-Life Care for Hematologic MalignanciesThomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.
Latest:
HPV Test With Genotyping Tops Cervical Cancer Screening StrategiesCervical cancer screening based on identification of human papillomavirus (HPV) strains outperformed primary liquid cytology for detection of high-grade cervical intraepithelial neoplasia (CIN), data from a large cohort study showed.
Latest:
Dr Zhang on Topics of Ongoing Debate Within Prostate CancerTian Zhang, MD, MHS, discusses areas of ongoing debate regarding prostate cancer management.
